The goal of the Eastern Cooperative Oncology Group (ECOG) CCOP program is to promote the development of state-of-the-art NCI-approved cancer prevention and control intervention protocols and to continue serving as a Research Base for CCOP members of the group.
Specific Aims i nclude: 1. To focus on biomarker-driven drug development for cancer prevention and cancer therapy;2. To contribute to state-of-the-science research in outcomes measurement and analysis in the context of cancer clinical trials;3. To enroll patients into high-quality, meaningful symptom management trials that add to our understanding of the prevention or elimination of suffering attributable to cancer;4. To advance our understanding of cancer survivorship and design interventions to address these issues;5. To continue to develop treatment protocols particularly suitable for the CCOP members of ECOG;6. To expand development of programs to increase the accrual of minority populations to ECOG trials with a focus on disparity intervention. 7. To improve overall support for protocol development, data management, and analysis by providing a dedicated infrastructure within the ECOG Coordinating Center for the cancer control and prevention program. 8. To foster collaboration between disease and modality committees and the Symptom Management, Prevention, and Patient Outcomes and Survivorship Committees.
|Pili, Roberto; Jegede, Opeyemi; Carducci, Michael A et al. (2017) A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805]). Clin Genitourin Cancer 15:642-651.e1|
|Bhatia, Aarti K; Lee, Ju-Whei; Pinto, Harlan A et al. (2017) Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer 123:4653-4662|
|Cohee, Andrea A; Adams, Rebecca N; Fife, Betsy L et al. (2017) Relationship Between Depressive Symptoms and Social Cognitive Processing in Partners of Long-Term Breast Cancer Survivors. Oncol Nurs Forum 44:44-51|
|Cohee, Andrea A; Adams, Rebecca N; Johns, Shelley A et al. (2017) Long-term fear of recurrence in young breast cancer survivors and partners. Psychooncology 26:22-28|
|Cohee, Andrea A; Stump, Timothy; Adams, Rebecca N et al. (2016) Factors associated with depressive symptoms in young long-term breast cancer survivors. Qual Life Res 25:1991-7|
|Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2016) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol :|
|Tevaarwerk, Amye J; Lee, Ju-Whei; Terhaar, Abigail et al. (2016) Working after a metastatic cancer diagnosis: Factors affecting employment in the metastatic setting from ECOG-ACRIN's Symptom Outcomes and Practice Patterns study. Cancer 122:438-46|
|Fisch, Michael J; Zhao, Fengmin; Manola, Judith et al. (2015) Patterns and predictors of antidepressant use in ambulatory cancer patients with common solid tumors. Psychooncology 24:523-32|
|Willis, Scooter; De, Pradip; Dey, Nandini et al. (2015) Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs. Meta Gene 4:129-41|
|Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2015) Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 373:2005-14|
Showing the most recent 10 out of 83 publications